DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart

Not Applicable

Completed

Conditions: Acute Leukemia in Remission
Hematopoietic Cell Transplantation Recipient
Lymphoma

Interventions: Device: Monitoring Device
Other: Informational Intervention
Other: Questionnaire Administration

First Posted Date: 2018-06-29

Last Posted Date: 2024-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 41

Registration Number: NCT03574012

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Gemtuzumab Ozogamicin
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2018-05-22

Last Posted Date: 2023-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT03531918

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers

Not Applicable

Completed

Conditions: Hematopoietic Cell Transplantation Recipient

Interventions: Behavioral: Booklet
Behavioral: Exercise Intervention
Other: Quality-of-Life Assessment
Other: Survey Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2018-05-15

Last Posted Date: 2020-03-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03525106

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

Not Applicable

Completed

Conditions: Anatomic Stage IIA Breast Cancer AJCC v8
Cancer Survivor
Prognostic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
HER2/Neu Negative
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Progesterone Receptor Positive
Prognostic Stage II Breast Cancer AJCC v8

Interventions: Other: Informational Intervention
Behavioral: Exercise Intervention
Other: Laboratory Biomarker Analysis
Device: Monitoring Device
Other: Questionnaire Administration
Other: Physical Performance Testing

First Posted Date: 2018-05-14

Last Posted Date: 2019-07-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT03523195

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Phase 1

Completed

Conditions: Anatomic Stage IIIC Breast Cancer AJCC v8
Invasive Breast Carcinoma
Prognostic Stage IIB Breast Cancer AJCC v8
Breast Cancer Female
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8

Interventions: Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Capecitabine
Procedure: Biospecimen Collection

First Posted Date: 2018-05-08

Last Posted Date: 2022-06-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03518242

Locations: 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇬
New Mulago Hospital, Kampala, Uganda

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Acute Myeloid Leukemia
Minimal Residual Disease Negativity

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Etoposide
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-05-03

Last Posted Date: 2021-02-01

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03515707

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Phase 1

Terminated

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: BCMA-specific CAR-expressing T Lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Gamma-Secretase Inhibitor LY3039478
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic Study

First Posted Date: 2018-04-18

Last Posted Date: 2024-01-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 19

Registration Number: NCT03502577

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Biological: Immunosuppressive Therapy
Other: Survey Administration

First Posted Date: 2018-03-30

Last Posted Date: 2021-06-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT03483675

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI

Completed

Conditions: Hematopoietic Malignancy

First Posted Date: 2018-02-15

Last Posted Date: 2023-05-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 360

Registration Number: NCT03434561

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome With Excess Blasts

Interventions: Biological: Dilanubicel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Other: Laboratory Biomarker Analysis
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Multigated Acquisition Scan
Procedure: Electrocardiography
Procedure: Computed Tomography

First Posted Date: 2018-01-16

Last Posted Date: 2025-04-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03399773

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy